Nightingale Health Ltd. and PerkinElmer, Inc. have announced a strategic collaboration to develop novel precision medicine solutions to address the global burden of diseases. Nightingale has developed an internationally recognized NMR (Nuclear Magnetic Resonance) based biomarker analysis assay for disease screening, diagnostics and treatment efficacy assessment. PerkinElmer is a global leader in laboratory equipment and consumables, including diagnostic devices committed to innovating for a healthier world.
"Nightingale's mission is solving the global burden of chronic diseases. Our assay is built upon an unrivalled scientific foundation, with over 100 peer-reviewed publications in leading biomedical journals. We believe our analysis technology has the potential to make a considerable contribution to society, through improving early disease detection in healthcare, and particularly in primary care," said Teemu Suna, CEO and Founder, Nightingale Health.
Chronic diseases including heart disease, stroke, cancer, chronic respiratory diseases and diabetes, are the leading cause of mortality in the world, but it's thought that 80% of premature heart disease, stroke and diabetes are broadly preventable.
As the global leader in newborn screening, PerkinElmer currently serves customers in more than 100 countries worldwide. Its customers have screened more than 600 million babies throughout the world for life-threatening diseases, helping to save 70 newborns per day (25,000 per year). Through its integrated laboratories in the U.S. and India, PerkinElmer also offers a global genomic lab testing platform that performs newborn screening, diagnostic testing and genetic sequencing services.
"Until now, metabolomic analyses have been prohibitively expensive and too complex to enable extensive screening, and therefore have failed to keep pace with developments in genomic sequencing. Comprehensive metabolic profiling of blood biomarkers can provide an accurate assessment of the molecular effects of many metabolic diseases, complementing genomic information obtained from gene panels, whole exome sequencing (WES), and whole-genome sequencing (WGS)," said Karen Madden, Vice President, Technology & Innovation, PerkinElmer. "We look forward to working with Nightingale to develop a comprehensive solution including both Nightingale's innovative assay and PerkinElmer's sequencing services across a range of healthcare applications."
"Nightingale has a great team of supporters around it. We are targeting the creation of an international growth company and the outlook couldn't be better. I'm extremely proud of Nightingale's team, but this is just the beginning of our journey," said Mr. Suna. "During the previous two years, we have gone through an extensive R&D and business development phase, and are now quickly entering the scale-out phase of our operations."
Nightingale has raised around EUR 25M in the last thirty months as equity investments, non-equity loans, and income financing, to pursue further development and commercialization.